Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 12/20 | 0.82 |
| ▸ | EDNRA | P25101 | 12/20 | 0.82 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7443267 | 1.00 | EDNRB (0.82) | EDNRBEDNRAACEECE1TACR1 | |
| SCHEMBL29551459 | 1.00 | EDNRB (0.82) | EDNRBEDNRAACEECE1TACR1 | |
| SCHEMBL18222569 | 1.00 | EDNRB (0.82) | EDNRBEDNRAACEECE1TACR1 | |
| SCHEMBL8721945 | 0.96 | EDNRB (0.78) | EDNRBEDNRAACETACR1 | |
| SCHEMBL8721943 | 0.96 | EDNRB (0.78) | EDNRBEDNRAACETACR1 | |
| SCHEMBL18222567 | 0.96 | EDNRB (0.78) | EDNRBEDNRAACETACR1 | |
| SCHEMBL21427022 | 0.94 | EDNRB (0.76) | EDNRBEDNRAACEECE1 | |
| SCHEMBL8721117 | 0.94 | EDNRB (0.76) | EDNRBEDNRAACETACR1 | |
| SCHEMBL8722706 | 0.94 | EDNRB (0.76) | EDNRBEDNRAACETACR1 | |
| SCHEMBL8722703 | 0.94 | EDNRB (0.76) | EDNRBEDNRAACETACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160331783-A1 | BISAMIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR REDUCING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | claimed |
| US-20210077562-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | ENB THERAPEUTICS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210077562-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | ENB THERAPEUTICS, INC. | 2021-03-18 | — | — | US | disclosed |
| EP-3746110-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | ENB Therapeutics, Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20190314444-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | ENB THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190314444-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | ENB THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019191721-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | ENB THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019191721-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | ENB THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20160331783-A1 | BISAMIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR REDUCING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| EP-0753004-A1 | ANTAGONISTS OF ENDOTHELIN RECEPTORS | Japat Ltd (CH) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995026360-A1 | ANTAGONISTS OF ENDOTHELIN RECEPTORS | JAPAT LTD. (CH) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314444-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | EDNRB, EDNRA, LTB4R | EDNRB 1/4885EDNRA 2/4885ACE 619/4885 |
| US-20160331783-A1 | BISAMIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR REDUCING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | HBB, HBG2, HBG1 | EDNRB 259/4885EDNRA 205/4885ACE 4369/4885 |
| US-20210077562-A1 | ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES | EDNRB, EDNRA, LTB4R | EDNRB 1/4885EDNRA 2/4885ACE 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.